Abstract
TERT promoter (TERTp) mutations widely occur in multiple human neoplasms, and they have been related to different clinicopathological features. To date, this mutation has not been identified in sebaceous tumors. Here, we analyzed TERTp mutations in 91 sebaceous neoplasms (17 adenomas, 45 sebaceomas, and 29 carcinomas). We detected mutations in 26.7% (8 of 29) of sebaceous carcinomas by pyrosequencing and Sanger sequencing. No mutation was detected in adenomas or sebaceomas. The difference was significant between sebaceoma and carcinoma. The most frequent TERTp mutations were C228T and C250T in 37.5% (3 of 8) of mutated cases each one. The mutation was not associated with poor clinical evolution. Using NGS, 20 of 29 (68.5%) sebaceous carcinomas harbored mutations in 8 of the 30 genes analyzed (TP53, TERTp, EGFR, ATRX, PDGFRA, CDKN2A, PTEN, and ACVR1). With immunohistochemistry, only 1 of 8 (12.5%) TERTp-mutated carcinomas lacked mismatch repair (MMR) protein expression compared to 6 of 21 (31.6%) of non-mutated ones. Sebaceous carcinomas with MMR protein expression had significantly higher frequency of total mutations and TP53 and TERTp mutations than MMR protein-deficient carcinomas. In conclusion, TERTp mutation has been detected in sebaceous carcinomas, and its presence could be useful to differentiate sebaceous carcinoma from sebaceoma, a difficult histopathological challenge.
Similar content being viewed by others
Data Availability
All data generated or analyzed during this study are included in this published article and its supplementary information file.
References
Flux K (2017) Sebaceous neoplasms. Surg Pathol Clin 10(2):367–382
Wick MR, Cree IA, Kazakov DV et al (2018) Tumours with sebaceous differentiation. In: Elder ED, Massi D, Scolyer RA, Willemze R (eds) WHO classification of skin tumours, 4th edn. IARC, Lyon, pp 211–215
Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B (2016) Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84–95
Harvey NT, Tabone T, Erber W, Wood BA (2016) Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis. Pathology. 48(5):454–462
John AM, Schwartz RA (2016) Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol 74(3):558–566
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science. 339(6122):959–961
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science. 339(6122):957–959
Griewank KG, Murali R, Schilling B, Schimming T, Möller I, Moll I, Schwamborn M, Sucker A, Zimmer L, Schadendorf D, Hillen U (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8(11):e80354
Lin SY, Liao SL, Hong JB, Chu CY, Sheen YS, Jhuang JY, Tsai JH, Liau JY (2016) TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis. Br J Ophthalmol 100(2):274–277
Labussière M, Di Stefano AL, Gleize V et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111(10):2024–2032
Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73(24):7162–7167
Liu R, Xing M (2016) TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 23(3):R143–R155
Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, Grob TJ (2014) Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch 465(6):673–677
Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T (2014) TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 27(4):502–508
D’Haene N, Meléndez B, Blanchard O, de Nève N, Lebrun L, van Campenhout C, Salmon I (2019) Design and validation of a gene-targeted, next-generation sequencing panel for routine diagnosis in gliomas. Cancers (Basel) 11(6):773
Cantero D, Mollejo M, Sepúlveda JM et al (2020) TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv 2(1):vdz059
R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna Available at: https://www.R-project.org/
Colebatch AJ, Dobrovic A, Cooper WA (2019) TERT gene: its function and dysregulation in cancer. J Clin Pathol 72(4):281–284
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, DiCara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DSB, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012 Jul 20) A landscape of driver mutations in melanoma. Cell. 150(2):251–263
Heidenreich B, Kumar R (2017) TERT promoter mutations in telomere biology. Mutat Res 771:15–31
Acknowledgements
We acknowledge Dr. Isabelle Salmon, Dr. Nicky D’Heane, and Dr. Bárbara Meléndez from the Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium, for generously providing the NGS panel.
Funding
No funding was received for conducting this study.
Author information
Authors and Affiliations
Contributions
Conceptualization: María-Teresa Muñoz-Jiménez, Erika Riveiro-Falkenbach, José-Luis Rodríguez-Peralto, María Concepción Garrido; methodology: Leyla Blanco, Yolanda Ruano, María-Teresa Muñoz-Jiménez, Erika Riveiro-Falkenbach, José-Luis Rodríguez-Peralto, María Concepción Garrido; formal analysis and investigation: Leyla Blanco, Yolanda Ruano, María-Teresa Muñoz-Jiménez; writing—original draft preparation: María-Teresa Muñoz-Jiménez; writing—review and editing: José Luis Rodríguez-Peralto, Yolanda Ruano, María-Teresa Muñoz-Jiménez, María Concepción Garrido; resources: José-Luis Rodríguez-Peralto, María Concepción Garrido, Rosario Carrillo, Heinz Kutzner, Luis Requena, Ángel Santos-Briz; supervision: José-Luis Rodríguez-Peralto, María Concepción Garrido, Yolanda Ruano.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the institutional ethics committee.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Conflicts of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(PDF 61 kb)
Rights and permissions
About this article
Cite this article
Muñoz-Jiménez, MT., Blanco, L., Ruano, Y. et al. TERT promoter mutation in sebaceous neoplasms. Virchows Arch 479, 551–558 (2021). https://doi.org/10.1007/s00428-021-03083-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-021-03083-9